A panel of speakers involved in cutting-edge studies on the biological and cellular bases for therapeutic response in cancer will share their vision on how these disruptive discoveries could be exploited to rethink cancer therapies to ultimately improve therapeutics. Topics to be covered include: the role of mitochondrial homeostasis in therapy response; the latest and most disruptive advances in the molecular pharmacology of historical chemotherapeutic agents; the tumour microenvironment; experimental therapeutics in models systems; and more.
Target audience: medical/clinical oncologists with an interest in translational research, biology, and pharmacology; basic scientists with an interest in translational research and preclinical models; and colleagues from industry with a focus on molecular pharmacology and drug repositioning.
Speakers: Renata Basto (Institut Curie, France), Filipe Cabriero (MRC London Institute of Medical Sciences, UK), Huges de Thé (Institut Jean Bernard, France), Fanny Jaulin (Gustave Roussy, France), Valerie Lallemand-Breitenbach (INSERM, France), Scott Lowe (Memorial Sloan Kettering Cancer Center, USA), Fatima Mechta-Grigoriou (Institut Curie, France), Patrick Mehlen (Lyon Cancer Research Center, France), Yves Pommier (NCI Center for Cancer Research, USA), Sophie Postel-Vinay (IGR, France), Jean-Emmanuel Sarry (Centre de Recherches en Cancérologie de Toulouse, France), Clemens Schmitt (Max Delbruck Center, Germany), Jean Soulier (INSERM, France), Andreas Trumpp (German Cancer Research Centre, Germany), Celine Vallot (Institut Curie, France)
Keywords: cellular basis, cancer response, patient response, cell line, chemotherapy, hormone therapy, in vivo models, in vivo validated cellular effects, mechanism-based combinations, novel molecular pathways, anticancer therapy, biological basis for therapeutic response, mitochondrial homeostasis, chemotherapy agents, tumor microenvironment, experimental therapeutics, drug repositioning, cancer research, oncology
Target audience: medical/clinical oncologists with an interest in translational research, biology, and pharmacology; basic scientists with an interest in translational research and preclinical models; and colleagues from industry with a focus on molecular pharmacology and drug repositioning.
Speakers: Renata Basto (Institut Curie, France), Filipe Cabriero (MRC London Institute of Medical Sciences, UK), Huges de Thé (Institut Jean Bernard, France), Fanny Jaulin (Gustave Roussy, France), Valerie Lallemand-Breitenbach (INSERM, France), Scott Lowe (Memorial Sloan Kettering Cancer Center, USA), Fatima Mechta-Grigoriou (Institut Curie, France), Patrick Mehlen (Lyon Cancer Research Center, France), Yves Pommier (NCI Center for Cancer Research, USA), Sophie Postel-Vinay (IGR, France), Jean-Emmanuel Sarry (Centre de Recherches en Cancérologie de Toulouse, France), Clemens Schmitt (Max Delbruck Center, Germany), Jean Soulier (INSERM, France), Andreas Trumpp (German Cancer Research Centre, Germany), Celine Vallot (Institut Curie, France)
Keywords: cellular basis, cancer response, patient response, cell line, chemotherapy, hormone therapy, in vivo models, in vivo validated cellular effects, mechanism-based combinations, novel molecular pathways, anticancer therapy, biological basis for therapeutic response, mitochondrial homeostasis, chemotherapy agents, tumor microenvironment, experimental therapeutics, drug repositioning, cancer research, oncology
